JP2010536896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536896A5 JP2010536896A5 JP2010522210A JP2010522210A JP2010536896A5 JP 2010536896 A5 JP2010536896 A5 JP 2010536896A5 JP 2010522210 A JP2010522210 A JP 2010522210A JP 2010522210 A JP2010522210 A JP 2010522210A JP 2010536896 A5 JP2010536896 A5 JP 2010536896A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- acute
- chronic
- lymphocytic leukemia
- myeloid leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007041115A DE102007041115A1 (de) | 2007-08-30 | 2007-08-30 | Thiadiazinonderivate |
| DE102007041115.6 | 2007-08-30 | ||
| PCT/EP2008/006466 WO2009030333A1 (de) | 2007-08-30 | 2008-08-06 | Thiadiazinonderivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536896A JP2010536896A (ja) | 2010-12-02 |
| JP2010536896A5 true JP2010536896A5 (enExample) | 2014-04-03 |
| JP5524840B2 JP5524840B2 (ja) | 2014-06-18 |
Family
ID=39952448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522210A Expired - Fee Related JP5524840B2 (ja) | 2007-08-30 | 2008-08-06 | チアジアジノン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8211886B2 (enExample) |
| EP (1) | EP2181111B1 (enExample) |
| JP (1) | JP5524840B2 (enExample) |
| KR (1) | KR20100065171A (enExample) |
| CN (1) | CN101784544B (enExample) |
| AR (1) | AR068130A1 (enExample) |
| AU (1) | AU2008295193B2 (enExample) |
| BR (1) | BRPI0816058A2 (enExample) |
| CA (1) | CA2698062C (enExample) |
| DE (1) | DE102007041115A1 (enExample) |
| EA (1) | EA017393B1 (enExample) |
| ES (1) | ES2426356T3 (enExample) |
| IL (1) | IL204127A (enExample) |
| MX (1) | MX2010002096A (enExample) |
| WO (1) | WO2009030333A1 (enExample) |
| ZA (1) | ZA201002218B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| DE4310699A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Thiadiazinone |
| AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE19604388A1 (de) | 1996-02-07 | 1997-08-14 | Merck Patent Gmbh | Arylalkyl-diazinone |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP2017266A1 (en) | 1997-11-19 | 2009-01-21 | Kowa Co., Ltd. | Pyridazine derivatives and medicines containing the same as effective ingredients |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| US20040259863A1 (en) | 2001-10-31 | 2004-12-23 | Hans-Michael Eggenweiler | Type 4 phosphodiesterase inhibitors and uses thereof |
| DE102005055355A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| DE102005055354A1 (de) | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
-
2007
- 2007-08-30 DE DE102007041115A patent/DE102007041115A1/de not_active Withdrawn
-
2008
- 2008-08-06 JP JP2010522210A patent/JP5524840B2/ja not_active Expired - Fee Related
- 2008-08-06 BR BRPI0816058 patent/BRPI0816058A2/pt not_active IP Right Cessation
- 2008-08-06 ES ES08785386T patent/ES2426356T3/es active Active
- 2008-08-06 MX MX2010002096A patent/MX2010002096A/es active IP Right Grant
- 2008-08-06 CN CN2008801040992A patent/CN101784544B/zh not_active Expired - Fee Related
- 2008-08-06 EA EA201000364A patent/EA017393B1/ru not_active IP Right Cessation
- 2008-08-06 EP EP08785386.7A patent/EP2181111B1/de active Active
- 2008-08-06 KR KR1020107006823A patent/KR20100065171A/ko not_active Withdrawn
- 2008-08-06 WO PCT/EP2008/006466 patent/WO2009030333A1/de not_active Ceased
- 2008-08-06 AU AU2008295193A patent/AU2008295193B2/en not_active Ceased
- 2008-08-06 CA CA2698062A patent/CA2698062C/en active Active
- 2008-08-06 US US12/675,412 patent/US8211886B2/en not_active Expired - Fee Related
- 2008-08-29 AR ARP080103757A patent/AR068130A1/es unknown
-
2010
- 2010-02-23 IL IL204127A patent/IL204127A/en active IP Right Grant
- 2010-03-29 ZA ZA2010/02218A patent/ZA201002218B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513418A5 (enExample) | ||
| CN110545800A (zh) | 用于靶向活化cd44分子的纳米钙载体递送系统、其制备方法和用途 | |
| JP2010532774A5 (enExample) | ||
| JP2012501986A5 (enExample) | ||
| JP2010538767A5 (enExample) | ||
| WO2009108856A3 (en) | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| WO2009105513A8 (en) | Novel compounds and methods for therapy | |
| MY160445A (en) | Dual Variable Domain Immunoglobulins And Uses Thereof | |
| CA2726087A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2009537552A5 (enExample) | ||
| IT1395519B1 (it) | Pezzo composito, nonche' impiego del pezzo composito | |
| JP2013074936A5 (enExample) | ||
| WO2009074328A8 (en) | Methods and nucleic acids for analyses of lung carcinoma | |
| EP3702782A3 (en) | Methods and compositions for amplified electrochemiluminescence detection | |
| EP4279925A3 (en) | Dulaglutide for the treatment of chronic kidney disease | |
| WO2009127414A3 (en) | Inhibition of angiogenesis and tumor metastasis | |
| JP2011520996A5 (enExample) | ||
| JP2009519974A5 (enExample) | ||
| JP2008542528A5 (enExample) | ||
| JP2009532412A5 (enExample) | ||
| WO2011051271A3 (en) | Prostate tumor markers and methods of use thereof | |
| MX2009011388A (es) | Inhibidores de polimerasa y su uso para el tratamiento de tumores. | |
| BRPI0822415A2 (pt) | Conjugado de hidróxipolímero modificado, uso de conjugado de hidroxipolímero modificado, composição para matar tumor, e, métodos para produzir o conjugado de hidroxipolímero modificado e para tratar câncer. | |
| CL2014001823A1 (es) | Procedimiento de preparacion estereoselectiva de un compuesto derivado de 9-hidroxi-5-oxo-1,4-diaza-espiro [5.5] undecano; compuestos intermediarios; uso en el tratamiento de enfermedades tumorales, enfermedades del pulmon y de las vias respiratorias. |